MLNM Phase II LDP-341 myeloma data

Millennium (MLNM) said that in an ongoing 150-patient U.S. Phase II trial, its LDP-341 proteasome inhibitor reduced levels of M protein (a marker of myeloma severity) by at least 50% in 22 of 54 evalu...